PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

Phase 3

Recruiting

Conditions: Hemophilia B
Hemophilia A

Interventions: Diagnostic Test: Testing of hepatic AAV Vector integration

First Posted Date: 2022-10-06

Last Posted Date: 2025-04-11

Lead Sponsor: Pfizer

Target Recruit Count: 263

Registration Number: NCT05568719

Locations: 🇺🇸
UC Davis Health, Sacramento, California, United States
🇺🇸
UC Davis Ambulatory Care Clinic, Sacramento, California, United States
🇺🇸
UC Davis Hemophilia Treatment Center, Sacramento, California, United States

and more 8 locations

A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies

Phase 1

Completed

Conditions: Lymphoma
Multiple Myeloma

Interventions: Drug: maplirpacept (PF-07901801)

First Posted Date: 2022-10-05

Last Posted Date: 2024-11-06

Lead Sponsor: Pfizer

Target Recruit Count: 7

Registration Number: NCT05567887

Locations: 🇯🇵
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi, Japan
🇯🇵
Yamagata University Hospital, Yamagata, Japan
🇯🇵
Japanese Foundation for Cancer Research, Koto, Tokyo, Japan

and more 1 locations

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: nirmatrelvir
Drug: ritonavir
Drug: placebo for nirmatrelvir

First Posted Date: 2022-10-05

Last Posted Date: 2024-10-08

Lead Sponsor: Pfizer

Target Recruit Count: 436

Registration Number: NCT05567952

Locations: 🇺🇸
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
🇺🇸
Mercury Street Medical Group, PLLC, Butte, Montana, United States
🇺🇸
Global Health Clinical Trials, Miami, Florida, United States

and more 78 locations

A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer

Terminated

Conditions: Bladder Cancer

Interventions: Drug: Avelumab

First Posted Date: 2022-10-05

Last Posted Date: 2023-07-13

Lead Sponsor: Pfizer

Target Recruit Count: 19

Registration Number: NCT05568407

Locations: 🇧🇷
Hospital Moinhos de Vento, Porto Alegre, RIO Grande DO SUL, Brazil
🇧🇷
Hospital Mãe de Deus/Aesc, Porto Alegre, RIO Grande DO SUL, Brazil
🇧🇷
Hospital Alemão Oswaldo Cruz, Sao Paulo, SP, Brazil

and more 4 locations

A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Standard of care
Drug: Elranatamab

First Posted Date: 2022-10-04

Last Posted Date: 2024-05-21

Lead Sponsor: Pfizer

Target Recruit Count: 508

Registration Number: NCT05565391

Locations: 🇺🇸
Pfizer, New York, New York, United States

Resolution of Sickle Cell Leg Ulcers With Voxelotor

Phase 3

Terminated

Conditions: Sickle Cell Disease
Leg Ulcers

Interventions: Drug: Voxelotor Oral Tablet
Other: Placebo

First Posted Date: 2022-09-30

Last Posted Date: 2024-11-14

Lead Sponsor: Pfizer

Target Recruit Count: 88

Registration Number: NCT05561140

Locations: 🇰🇪
KEMRI-Centre for Respiratory Diseases Research-Nairobi, Nairobi, Kenya
🇰🇪
Strathmore University Medical Centre, Nairobi, Kenya
🇰🇪
KEMRI-CRDR, KEMRI Clinical Research Annex, Siaya, Kenya

and more 17 locations

Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.

Completed

Conditions: Hereditary Transthyretin Amyloidosis (ATTRv)
Polyneuropathy

Interventions: Drug: Tafamidis

First Posted Date: 2022-09-29

Last Posted Date: 2024-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 5

Registration Number: NCT05560555

Locations: 🇪🇸
Hospital Clinico San Carlos, Madrid, Spain
🇪🇸
Hospital Universitari de Bellvitge, Barcelona, Spain
🇪🇸
Hospital Son Llatzer, Palma de Mallorca, Spain

A Study to Learn About the Study Medicine Called CTB+AVP in Healthy Adult People.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-07612577
Drug: Placebo
Drug: PF-06264006

First Posted Date: 2022-09-26

Last Posted Date: 2024-10-10

Lead Sponsor: Pfizer

Target Recruit Count: 42

Registration Number: NCT05554237

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

Phase 1

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: PF-07054894
Drug: Placebo

First Posted Date: 2022-09-22

Last Posted Date: 2025-04-16

Lead Sponsor: Pfizer

Target Recruit Count: 27

Registration Number: NCT05549323

Locations: 🇺🇸
IHS Health Research, Kissimmee, Florida, United States
🇺🇸
Kissimmee Endosocpy Center ( Endoscopy Only ), Kissimmee, Florida, United States
🇺🇸
Orlando Diagnostic Center ( CXR Only ), Kissimmee, Florida, United States

and more 14 locations

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: ARV-471
Drug: Abemaciclib

First Posted Date: 2022-09-21

Last Posted Date: 2025-04-29

Lead Sponsor: Pfizer

Target Recruit Count: 37

Registration Number: NCT05548127

Locations: 🇺🇸
Stanford Women's Cancer Center, Palo Alto, California, United States
🇺🇸
UCSF Medical Center at Mission Bay, San Francisco, California, United States
🇺🇸
Moffitt Cancer Center - International Plaza, Tampa, Florida, United States

and more 27 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy